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Spina bifida is among the phenotypes of the larger condition known as neural tube defects (NTDs). It is the most common central
nervous systemmalformation compatiblewith life and the second leading cause of birth defects after congenital heart defects. In this
review paper, we define spina bifida and discuss the phenotypes seen in humans as described by both surgeons and embryologists in
order to compare and ultimately contrast it to the leading animal model, the mouse. Our understanding of spina bifida is currently
limited to the observations we make in mouse models, which reflect complete or targeted knockouts of genes, which perturb the
whole gene(s) without taking into account the issue of haploinsufficiency, which is most prominent in the human spina bifida
condition. We thus conclude that the need to study spina bifida in all its forms, both aperta and occulta, is more indicative of the
spina bifida in surviving humans and that the measure of deterioration arising from caudal neural tube defects, more commonly
known as spina bifida, must be determined by the level of the lesion both in mouse and in man.
1. Introduction
Spina bifida is the most common and complex central
nervous system malformation in humans. Management of
these patients involves various disciplines to ensure the best
possible outcome achieved and provide a good quality of
life for its patients [1, 2]. The study of this condition is
extremely relevant in that even in the 20 years since the
discovery of the benefits of folic acid this condition is
highly prevalent around the world and its occurrence does
not seem to decrease [3]. Interestingly, the debate is very
much ongoing upon the evidence that the United States
of America has seen a decline in cases of spina bifida
(https://www.cdc.gov/ncbddd/spinabifidadata.html). This
review paper intends to compare and contrast spina bifida in
humans and spina bifida in the mouse, which is the leading
animal model of this devastating condition in light of the
information studies on animal models have shed on the
human counterpart [4–6].
2. Spina Bifida in Humans
Development of the central nervous system including the
brain and spinal cord is a complex process beginning with
a flat sheet of cells which undergoes sequential thickening,
elevation, mediolateral convergence accompanied by rostro-
caudal extension, and finally adhesion to form the neural
tube (NT) which is the precursor of the brain and the
spinal cord. Perturbations of these interconnected processes
result in neural tube defects (NTDs), which are the most
common congenital malformation affecting this system and
are associated with significant complications. NTDs can
occur in two major forms: spina bifida (SB) aperta, which
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is the open-lesion NTD, and the closed-lesion NTD, more
commonly known as SB occulta.
3. Epidemiology
Spina bifida is the most common nonlethal malformation
in the spectrum of NTDs and has an incidence generally
around 0.5 per 1,000 births, although higher frequencies have
been reported [7–11]. In the United Kingdom, the population
prevalence of spina bifida is 7.8–8.4 per 10,000 for males and
9.0–9.4 per 10,000 for females [12]. While the prevalence in
the United States of America is more than 3 in every 10,000
births [8, 13], studies in parts of Asia, such as Malaysia, have
also shown a lower occurrence of spina bifida than that of the
UK [14]. More recent efforts by our group (“Spina Bifida: A
10-Year Retrospective Study at University of Malaya Medical
Centre, Malaysia,” manuscript in submission), however, have
found that the lower rate of NTDs may not be completely
representative as in our hospital alone from the years 2003
to 2012 we have had over 10 cases of neural tube defects per
year (spina bifida and anencephaly). Furthermore, certain
regions of China have shown much higher preponderance
of this condition than in other parts of the world [15–18]. In
Africa, for example, spina bifida has been recorded as being
low in occurrence in comparison to other birth defects but
questions have arisen with regard to record-taking and data
management [19]. Gender preponderance differs according
to country; in the USA, spina bifida is thought to be more
prevalent in girls than in boys [20, 21].
4. Pathogenesis
Spina bifida aperta (SBA), sometimes referred to as spina
bifida cystica, is usually visible at birth as an exposed neural
tissue with or without a protruding sac at the site of the lesion.
SBAmay be referred to as either myeloschisis (Figure 1(a)) or
myelomeningocele (Figure 1(b)). Myelomeningocele is when
the spinal cord protrudes from the spinal canal into a fluid-
filled sac resulting from incomplete closure of the primary
neural tube. Myeloschisis is when the incomplete closure of
the primary neural plate results in a cleft spinal cord with
the edges flush with the defect. The extent and severity of
the neurological deficits depend on the location of the lesion
along the neuraxis [22].
Meningocele (Figure 1(c)) is often described as a less
severe variant of myelomeningocele in which the spinal cord
is not found in the sac and is described by embryologists
to be absent of neural matter in its herniated sac; and its
description is often coupled with that of myelomeningocele
which clearly has neural matter herniating at the site of the
open lesion. Therefore, the status of meningocele being an
open (aperta) or closed (occulta) defect is still debatable
in terms of embryogenesis. However, imaging evidence by
radiologists has firmly placed meningocele as spina bifida
occulta [3, 7, 121–123].
Myelomeningocele (MMC) is usually associated with a
type II Chiari hindbrain malformation, ventriculomegaly,
and hydrocephalus [124, 125]. Chiari type II malformation
is the downward displacement of the cerebellar vermis into
the cervical vertebral canal [22, 125]. It is often symptomatic
and is diagnosed prenatally with ultrafast fetal magnetic
resonance imaging (MRI) [126, 127]. This malformation
causes elongation of the brain stem and obliteration of
the fourth ventricle, leading to obstruction of cerebrospinal
fluid circulation and development of hydrocephalus in 90%
of patients [22]. Treatment of such accompanying hydro-
cephalus is needed in about 82% of cases and involves
draining of cerebrospinal fluid into either the peritoneal or
other body cavity via a subcutaneous shunt [128].
Spina bifida occulta (SBO) is the second major form of
NTDs, where the site of the lesion is not left exposed [129,
130]. Spina bifida occulta encompasses lipomyelomeningo-
cele (Figure 1(d)), lipomeningocele (Figure 1(e)), and spinal
dorsal dermal sinus tract (Figure 1(f)) ranging phenotypically
from (i) dysplastic skin, (ii) tuft of hair, and (iii) vestigial
tail as well as other forms of spinal dysraphism, which
lack a pathogenic representation when the vertebrae develop
abnormally leading to absence of the neural arches [131, 132].
In symptomatic cases, tethering of the spinal cord within the
vertebral canal can result in pain, weakness, and incontinence
in otherwise normal, healthy children or adults [133].
5. Treatment and Management
Management of patients with myelomeningocele has
improved drastically from the mid-1970s when patients
were sometimes denied treatment based on the severity
of their condition [134] to the current state-of-the-art
prenatal in utero repairs performed at highly specialized
centers [127, 128]. Neonatal surgical closure of the lesion
is considered the standard of care against which all novel
management options are compared [22, 135, 136].
NTDs have a profound impact on society. The morbidity
and mortality rates of spina bifida patients decrease with
improving medical care. Taking the United Kingdom as an
example, Bowman et al. [137] in their 25-year follow-up of
71 spina bifida aperta patients found that at least 75% of these
children can be expected to reach their early adult years [137].
Moreover, as many as 85% are attending or have graduated
from high school and/or college. More than 80% of young
adults with spina bifida have social bladder continence. In the
same study, 49% had scoliosis, with 43% eventually requiring
a spinal fusion. Approximately one-third of patients were
allergic to latex, with six patients having experienced a life-
threatening reaction. Renal failure was 6.8–9.0 times more
common for males and 9.2–11.5 times more common for
female patients comparedwith the general population in each
of the years 1994–1997 in the UK [138]. Therefore, longer life
equates with the need for progressively better quality of life.
The sequelae of NTDs are staggering and appear to
have not only anatomical effects secondary to the primary
defect but also functional, emotional, and psychological
morbidities including bladder and bowel incontinence, paral-
ysis, musculoskeletal deformity, and shunt malfunctions and
infections, among others. Moreover, the costs involved in
maintenance of spina bifida patients include mobility aids
(orthoses, wheelchairs, and crutches), medications, and the
cost associated with shunt revisions, in addition to the cost
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Figure 1: Schematic representation of the open (aperta) and close (occulta) types of spina bifida. (a) Myeloschisis which represents the most
severe form of open spina bifida. (b) Myelomeningocele which represents another typical severe form of open spina bifida (spina bifida
aperta/spina bifida cystica).The typical representation is that of the spinal cord lying outside the spinal canal. (c) Meningocele that represents
open or close spina bifida (the skinmay ormay not be present) but spinal cord does not lie outside the spinal canal. (d) Lipomyelomeningocele
that represents closed spina bifida (spina bifida occulta) (covered with skin) but spinal cord is intermeshed with lipid globules (in yellow). (e)
Lipomeningocele that exhibits closed spina bifida but spinal cord does not lie outside spinal canal even though lipid globules are present. (f)
Spinal dorsal dermal sinus tract; spina bifida occulta with vertebral arches missing (often asymptomatic and is thought to be a mesodermal
defect and a defect of secondary neurulation).
of modifications to public utilities that are required to enable
disabled access. Ultimately, its compound nature results in an
immense financial burden amounting to $1,400,000 per child
affected by NTD over a 20-year life span [139–142].
5.1. Syndromic and Nonsyndromic (Isolated) Spina Bifida. A
small proportion of NTDs in live born infants are associated
with specific syndromes that are associated with chromo-
somal or single-gene disorders [143]. NTDs are currently
considered as “complex” disorders with genetic and envi-
ronmental factors playing roles in causation [144], which
have been summarized in Table 1. Craniorachischisis and
encephalocoele have the highest rate of syndromic associa-
tion, anencephaly and high spina bifida have intermediate
4 Scientifica
Ta
bl
e
1:
C
om
pr
eh
en
siv
el
ist
of
sy
nd
ro
m
ic
sp
in
ab
ifi
da
.
M
od
eo
f
in
he
rit
an
ce
C
on
di
tio
n
Re
fe
re
nc
es
Au
to
so
m
al
re
ce
ss
iv
e
(1
)J
ar
ch
o-
Le
vi
n
sy
nd
ro
m
e(
sp
on
dy
lo
co
st
al
dy
so
sto
sis
):
sh
or
te
ne
d
tr
un
k,
op
ist
ho
to
nu
sp
os
iti
on
of
th
eh
ea
d,
sh
or
tn
ec
k,
ba
rr
el-
sh
ap
ed
th
or
ax
,m
ul
tip
le
w
ed
ge
sh
ap
ed
an
d
bl
oc
k
ve
rt
eb
ra
e,
sp
in
ab
ifi
da
,a
nd
rib
an
om
al
ie
s.
(2
)C
er
eb
ro
co
sto
m
an
di
bu
la
rs
yn
dr
om
e:
Pi
er
re
Ro
bi
n
an
om
al
y,
sp
ee
ch
di
ffi
cu
lti
es
,s
ev
er
em
ic
ro
gn
at
hi
aw
ith
gl
os
so
pt
os
is,
sm
al
lt
ho
ra
x
w
ith
rib
-g
ap
de
fe
ct
s,
oc
ca
sio
na
li
nt
el
le
ct
ua
li
m
pa
irm
en
t,
an
d
sp
in
ab
ifi
da
.
(3
)H
um
an
at
hy
m
ic
nu
de
/S
CI
D
:T
-c
el
ld
ef
ec
t,
co
ng
en
ita
la
lo
pe
ci
a,
na
il
dy
st
ro
ph
y,
an
d
sp
in
ab
ifi
da
.
(4
)N
eu
-L
ax
ov
as
yn
dr
om
e:
sp
in
ab
ifi
da
,s
ev
er
ei
nt
ra
ut
er
in
eg
ro
w
th
re
ta
rd
at
io
n,
m
ic
ro
ce
ph
al
y,
pr
ot
ru
di
ng
ey
es
,a
bn
or
m
al
sk
in
,a
nd
lim
b
de
fe
ct
s.
(5
)P
H
AV
ER
sy
nd
ro
m
e:
sp
in
ab
ifi
da
,p
te
ry
gi
a,
he
ar
td
ef
ec
ts,
se
gm
en
ta
tio
n
de
fe
ct
so
ft
he
sp
in
e,
an
d
ra
di
ou
ln
ar
sy
no
sto
sis
.
[2
3–
35
]
Au
to
so
m
al
do
m
in
an
t
(1
)D
iG
eo
rg
es
yn
dr
om
e:
hy
po
ca
lc
em
ia
,p
ar
at
hy
ro
id
hy
po
pl
as
ia
,t
hy
m
ic
hy
po
pl
as
ia
,c
on
ot
ru
nc
al
ca
rd
ia
cd
ef
ec
ts,
an
d
fa
ci
al
fe
at
ur
es
.A
ca
se
of
as
so
ci
at
ed
sp
in
ab
ifi
da
w
as
re
po
rt
ed
.
(2
)W
aa
rd
en
bu
rg
sy
nd
ro
m
e:
Ty
pe
I,
w
id
eb
rid
ge
of
th
en
os
e,
la
te
ra
ld
isp
la
ce
m
en
to
ft
he
in
ne
rc
an
th
us
,p
ig
m
en
ta
ry
di
stu
rb
an
ce
of
fro
nt
al
w
hi
te
bl
az
eo
fh
ai
r,
he
te
ro
ch
ro
m
ia
iri
di
s,
w
hi
te
ey
el
as
he
s,
le
uk
od
er
m
a,
co
ch
le
ar
de
af
ne
ss
,a
nd
sp
in
ab
ifi
da
.
Ty
pe
II
I,
pa
rt
ia
la
lb
in
ism
,b
lu
ee
ye
s,
de
af
-m
ut
ism
,u
nd
ev
elo
pe
d
m
us
cle
s,
fu
se
d
jo
in
ts
in
th
ea
rm
s,
sk
el
et
al
dy
sp
la
sia
,a
nd
sp
in
ab
ifi
da
.
(3
)S
ac
ra
ld
ef
ec
tw
ith
an
te
rio
rm
en
in
go
ce
le
(S
D
A
M
):
sa
cr
al
ag
en
es
is
an
d
sp
in
ab
ifi
da
.
(4
)C
ze
iz
el
-L
os
on
ci
sy
nd
ro
m
e:
sp
lit
ha
nd
/s
pl
it
fo
ot
,h
yd
ro
ne
ph
ro
sis
,a
nd
sp
in
ab
ifi
da
.
[3
6–
45
]
X-
Li
nk
ed
(1
)F
oc
al
de
rm
al
hy
po
pl
as
ia
(m
al
el
et
ha
lit
y,
at
ro
ph
y
an
d
lin
ea
rp
ig
m
en
ta
tio
n
of
th
es
ki
n,
pa
pi
llo
m
as
of
sk
in
an
d
m
uc
os
ae
,o
cu
la
rd
ef
ec
ts,
hy
po
pl
as
tic
te
et
h,
an
d
di
gi
ta
la
no
m
al
ie
sa
pa
rt
fro
m
sp
in
ab
ifi
da
).
(2
)Z
ic
3
(s
pi
na
bi
fid
aw
ith
ab
do
m
in
al
sit
us
in
ve
rs
us
,c
om
pl
ex
ca
rd
ia
cd
ef
ec
ts,
as
pl
en
ia
,a
nd
po
ly
sp
le
ni
a)
.
(3
)C
on
ge
ni
ta
lh
em
id
ys
pl
as
ia
w
ith
ic
ht
hy
os
ifo
rm
er
yt
hr
od
er
m
aa
nd
lim
b
de
fe
ct
s(
CH
IL
D
sy
nd
ro
m
e)
.
[4
6–
48
]
Sp
or
ad
ic
(1
)I
so
la
te
d
he
m
ih
yp
er
pl
as
ia
:a
sy
m
m
et
ric
ov
er
gr
ow
th
of
on
eo
rm
or
er
eg
io
ns
w
ith
on
er
ep
or
te
d
ca
se
of
lu
m
ba
rm
ye
lo
m
en
in
go
ce
le.
(2
)D
ip
ro
so
pu
s:
co
nj
oi
ne
d
tw
in
sc
on
sis
tin
g
of
on
en
ec
k,
on
eb
od
y,
an
d
as
in
gl
eh
an
d
w
ith
va
rio
us
fo
rm
so
fd
up
lic
at
io
n
of
th
ec
ra
ni
of
ac
ia
l
st
ru
ct
ur
es
.M
ay
be
as
so
ci
at
ed
w
ith
sp
in
ab
ifi
da
.
(3
)P
en
ta
lo
gy
of
Ca
nt
re
ll:
m
id
lin
es
up
ra
um
bi
lic
al
ab
do
m
in
al
w
al
ld
ef
ec
t,
de
fe
ct
of
th
el
ow
er
ste
rn
um
,d
ef
ec
to
ft
he
di
ap
hr
ag
m
at
ic
pe
ric
ar
di
um
,d
efi
ci
en
cy
of
th
ea
nt
er
io
rd
ia
ph
ra
gm
,a
nd
co
ng
en
ita
lc
ar
di
ac
an
om
al
ie
s.
Sp
in
ab
ifi
da
ha
sb
ee
n
re
po
rt
ed
.
(4
)W
ei
ss
en
ba
ch
er
-Z
w
ey
m
u¨l
le
rs
yn
dr
om
e:
co
ng
en
ita
ln
eo
na
ta
lr
hi
zo
m
el
ic
dw
ar
fis
m
,m
et
ap
hy
se
al
w
id
en
in
g
of
th
el
on
g
bo
ne
s,
ve
rt
eb
ra
l
co
ro
na
lc
le
fts
,m
ic
ro
gn
at
hi
a,
cle
ft
pa
lat
e,
de
pr
es
se
d
na
sa
lr
oo
t,
hy
pe
rt
el
or
ism
,p
ro
tr
ud
in
g
ey
es
,o
cc
as
io
na
ls
en
so
rin
eu
ra
ld
ea
fn
es
s,
an
d
sp
in
a
bi
fid
a.
[4
9–
53
]
Scientifica 5
rates, and caudal spina bifida has the lowest rate [145]. The
role of folic acid in preventing syndromic NTDs turned
out to be not as gratifying as for nonsyndromic (isolated),
multifactorial NTDs [146]. It should be noted that while
syndromic NTDs may have identifiable genetic causes, many
of the nonsyndromic (isolated) NTDs have unidentified
genetic etiology. Most of human neural tube defects are
nonsyndromic with NTD being the only defect. The focus
of this review paper is on nonsyndromic (isolated) spina
bifida apart from the clearly stated syndromic spina bifida
mentioned specifically in Table 1.
5.2. Causative Factors, Detection, and Prevention of Spina
Bifida. The etiology of spina bifida is heterogeneous [147–
150]. Most nonsyndromic spina bifida is thought to be of
multifactorial origin [151] with influence of both genetic and
environmental factors [144, 152]. Among the environmental
factors associated with increased risk of spina bifida are
increased pregnancy weight [153–158], maternal smoking
[159–161], drug intake specifically of antiepileptic drugs [162–
164], and maternal illnesses such as diabetes [165, 166] and
hyperthermia [167]. Dietary factors includingwater chlorina-
tion [168–170], inositol intake [171], simple sugar intake [172],
and the intake of trace elements and other micronutrients
[173–176] have been proposed to act as either contributory
or preventive factors for spina bifida. Isolated spina bifida is
caused by cytogenetic abnormalities in 2–16% of cases [177–
179].
Elevated levels of maternal serum alpha-fetoprotein are
usually indicative of spina bifida aperta [180, 181] but can
be associated with other conditions (e.g., twin gestation
and abnormalities of placentation including placental lakes
and placenta previa) and ultrasound is needed to confirm
the diagnosis. Screening obstetrical ultrasonography is the
initial routine method for the detection of NTDs during
pregnancy in many countries. However, it sometimes fails
to detect closed spina bifida [182, 183]. In highly specialized
fetal centers, use of ultrafast fetal MRI has enabled detailed
anatomical evaluation of the defect and accurate assessment
of its accompanying effects [126].
It has been over 15 years since the Medical Research
Council Vitamin Trial involving 33 centers around the world
conclusively showed that 72% of recurrent NTD cases could
be prevented by folic acid supplements in the periconcep-
tional period [184]. A further study [185] showed that the
first occurrence of spina bifida could also be prevented by
folic acid. However, not all NTDs are responsive to folic
acid and inositol has been shown as a possible additional
therapy, based on prevention of spina bifida in folate-resistant
NTDs in mice as well as the PONTI human trial [186, 187].
Calcium formate too has been shown to have preventive
effects on NTD in mice but evidence is not yet forthcoming
in prevention of human NTDs [188–190]. There still remains
room to study whether there are other supplements out there
that can prevent spina bifida.
6. Surgical Management of Spina Bifida
Surgical management of spina bifida here is discussed as a
2-point discussion: first is surgical management prior to the
advent of in utero repair of open spina bifida and second is in
utero repair leading to the Management of Myelomeningo-
cele Study (MOMS) trial [128]. Postnatal repair of open spina
bifida repair is a requirement in order to prevent further
mechanical damage and infection. The lesion either may be
closed primarily with the aid of skin and muscle flaps or may
require a synthetic patch such as AlloDerm (LifeCell Corp.,
Branchburg, NJ) [191], gelatin, or collagen hybrid sponges
[192]. In utero MMC repair in humans was first reported
in the landmark paper published in 1998 [127]. However,
since then, a handful of centers have been offering in utero
repair. Furthermore, its popularity has increased in Europe
[193]. The principle of in utero repair is to prevent the 2-
hit hypothesis much described in previous literature that the
child is exposed to neurological deterioration contributed
first by failure of the neural tube to form and secondly by
physical and chemical perturbation inflicted on the exposed
neurological tissue of the open lesion [128, 194]. In an elegant
experimental study, Meuli et al. [195] concluded that surgical
exposure of the normal spinal cord to the amniotic space in a
75-day sheep fetus results in a MMC-type pathology at birth
with clinical, histological, andmorphological attributes com-
parable to humanMMC. Heffez et al. [196] has demonstrated
that spinal cord injury caused by exposure to the intrauterine
milieu can be prevented by primary closure of the fetal skin
incision as late as hours after creating the defect. It also
demonstrated that ongoing exposure beyond 24 hours leads
to spinal cord damage and permanent neurological deficit.
Moreover, animal studies have previously shown that prenatal
coverage of a spina bifida-like lesion preserves neurologic
function and improves hindbrain herniation [195, 197, 198].
The first human prenatal repair of MMC was reported
in Tulipan et al. [199]. Cumulative data suggested not only
a dramatic improvement in hindbrain herniation but also
increased maternal and neonatal risks including preterm
labor, uterine dehiscence, and increased risk of fetal and
neonatal death among others. Adzick et al. [128] investigated
the effects of prenatal repair of MMC via a randomized
prospective study. It reported that prenatal surgery for MMC
performed before 26 weeks of gestation decreased the risk
of death or need for shunting by the age of 12 months and
also improved scores on a composite measure of mental
and motor function, with adjustment for lesion level, at 30
months of age. Prenatal surgery also improves the degree of
hindbrain herniation associated with Chiari II malformation,
motor function, and the likelihood of being able to walk
independently, as compared with postnatal surgery [128].
Open prenatal repair comes with an increased maternal and
neonatal risk including preterm labor, uterine dehiscence,
premature rupture of membranes, and increased risk of fetal
and neonatal death. The main goal for prenatal repair of
MMC is to achieve skin closure to prevent further damage
of the placode and arrest the CSF leak.
7. Human Spina Bifida Genes
Despite the 250 mouse mutants with NTDs to date, there has
yet to be a significant breakthrough for human NTD gene(s)
both causal and/or associated with NTDs that can be used for
6 Scientifica
genetic screeningworldwide [4, 7].The importance of finding
candidate gene(s) as a genetic screening tool for potential
parents cannot be undervalued as it has been estimated that
the total lifetime costs for patients with spina bifida (spinal
NTDs) amount to about $1.4 million in the US and more
than €500k in Europe, with 37.1% of the total cost attributed
to direct medical costs and the remainder in indirect costs,
including the needs of the caregiver [200].
Despite observation of multiplex nonsyndromic NTD
cases in multigenerational NTD families as seen in 17 US and
14 Dutch families with more than 1 NTD-affected person,
there are other NTD cases that are simplex and sporadic as
seen in identical twins with lumbosacral lipomyelomeningo-
cele with no known familiar history of NTDs [201, 202]. This
suggests that NTDs have a multifactorial genetic etiology.
To date, the strongest candidate thus far for a poten-
tial NTD screening gene is the methylenetetrahydrofolate
reductase (MTHFR) C677T (rs1801133) polymorphism in
populations of non-Latin origin (meta-analysis study) [203].
In recent meta-analysis study, Zhang et al. support the
significant association between C677T and NTDs in case-
control studies (22 studies, 2,602 cases, and 4,070 controls)
[204]. The second most studied MTHFR variant is A1298C,
which did not report any significant increase in risk of NTDs
[204]. Another meta-analysis study by Blom et al. (2006)
reported increased risk in mothers and associated with NTD
infants who are homozygous for C677T variant [205]. In
spina bifida case studies, MTHFR C677T variant was clearly
reported as associated gene or risk factors in Irish (451 spina
bifida patients), mixed USA, mixed UK, and Italian cohort
but not in other 180 Dutch patients (Table 3), while A1298C
variant was reported with no association to spina bifida
cases in Italian, Mexican (Yucatan), and Dutch population
(Table 3). MTHFR is the most studied human spina bifida
gene, as its role in folate one-carbon metabolism fits into a
clearmechanism of NTD.However, the studies have not been
well replicated in many other populations across the world,
indicating that it is not likely to be either a major contributor
or a common factor in NTD globally.
Other genes such as the planar cell polarity (PCP) genes,
which have been studied in spina bifida cohorts among
Italians, Americans, and the French, areVANGL1 andCESLR1
[44, 82–84]. The noncore PCP gene SCRIB has also been
implicated as a spina bifida gene among the American cohort
[85]. However, noncore PCP gene association needs to be
explored further in larger NTD cohorts. To date, over 100
human spina bifida genes have been used to screen for spina
bifida with 48 genes reported as a potential risk factor as
listed in Table 3 which was reviewed in Greene et al. [93];
further candidates since then are NKX2-8, PTCH1, Glypican-
5, PARD3, Paraoxonase 1, COMT, AMT, andGLDC genes [16,
17, 206–211]. All of these do not represent a potential global
spina bifida gene. Therefore, a strong candidate spina bifida
gene(s) for the world population has yet to be discovered.
8. Spina Bifida in Mouse
There exist more than 250 mouse models with neural tube
defects, of which 74 are of spina bifida (Table 2) [4], yet there
does not exist a single mouse gene which can be used to
screen the orthologous human gene of neural tube defect nor
spina bifida to date [212]. That said, it does not mean that
the studies on the structural changes afforded by the mouse
model cannot be used as a tool to understand human spina
bifida. We discuss the various studies on mouse neurulation
below and why it is still an invaluable tool for understanding
human neurulation.
8.1. Mechanisms of Neural Tube Closure. In vertebrates, the
development of the CNS starts with the formation of the
neural plate on the dorsal surface of the embryo during late
gastrulation [213, 214]. A complex morphogenetic process
transforms the neural plate into the hollow neural tube in a
process known as “neurulation” [213]. Primary neurulation is
responsible for formation of the neural tube throughout the
brain and the spinal cord rostral to the mid-sacral level [215].
At more caudal levels, an alternative mechanism (secondary
neurulation) operates whereby the neural tube is formed by
canalization of a condensed rod of mesenchymal cells in the
tail bud [216].
The process of neurulation in mammals and some other
vertebrates is considered discontinuous because it occurs
simultaneously at multiple sites along the neuraxis [215–
219]. There are three points of de novo neural tube fusion
in the mouse, which is the most studied mammalian model
([220]; see Figure 2(a)). Closure 1 occurs adjacent to somite
3 in embryos with 6-7 somites and progresses rostrally and
caudally, closure 2 occurs at themidbrain-forebrain boundary
at around the 10-somite stage and progresses caudally, and
closure 3 occurs at the rostral end of the forebrain, soon after
closure 2.
Considering this discontinuous process of neurulation,
it can be understood why NTDs are such a complex group
of heterogeneous birth defects, with various phenotypic
presentations. Failure of closure 1 leads to craniorachischisis
(Figure 2(b)); failure of closures 2 and/or 3 causes exen-
cephaly and/or anencephaly, respectively (Figure 2(c)), while
failure of neurulation to progress from the site of closure
1 caudally along the spinal axis leads to spina bifida aperta
(Figure 2(d)).
During neurulation, the neuroepithelium must undergo
various structural changes in order to achieve closure. The
advent of molecular biology has allowed scientists to identify
the genes that are required for these structural changes to
occur. The next section gives a brief overview of the research
to date on how gene expression affects structural changes
in neural tube development, with an emphasis on gene
regulation in the spinal region.
8.2. The Structural Changes of the Mouse Neural Tube during
the Process of Closure. Morphologically, the mouse neural
tube undergoes distinct structural changes prior to its closure
[7, 215, 221–224]. A summary of the spatiotemporal expres-
sion of genes in the mouse neural tube during neurulation
is as shown in Table 5. The neuroepithelium narrows and
lengthens, a process referred to as convergent extension
(Figure 3(a)), in which the polarized cells which form the
neuroepithelial plate converge towards the midline, elongate
anteroposteriorly, and then intercalate [215, 225].
Scientifica 7
Table 2: List of mouse models that exhibits spina bifida (reviewed
in [4, 54]).
Mouse models
Gene or mutants (53 genes)
(1) Aln
(2) Ambra1
(3) Apapb
(4) Axdmutant
(5) Axin1
(6) Cyp26a1
(7) Dsmutant
(8) Dvl2
(9) Fgfr1 chimera
(10) Fkbp8 hypomorph
(11) Fpn1
(12) F2r, F2rl1 (Par1, Par2) (digenic)
(13) Grhl3
(14) Gnaz−/−; Grhl3Cre/+ (digenic)
(15) gGpr161 (vlmutant)
(16) ct mutant (Grhl3 hypomorph)
(17) Itgb1
(18) ltpk1
(19) Lrp6
(20) Lrp6 (rs mutant, hypomorph)
(21)Map3k4
(22)Mapk4 partial function
(23)Marcksl1 (Mlp)
(24)Med12
(25)Msgn1
(26)Msx1, Msx2 (digenic)
(27) Ndst1
(28) p28IP
(29) Pax3 (Spmutant)
(30) Pax3 (Sp2H)
(31) Pax3 (Spd)
(32) Ptpn9 (Meg2)
(33) Rab23 (opbmutant)
(34) Rab23 (opb2)
(35) Rac1−/−; 𝐺𝑟ℎ𝑙3𝐶𝑟𝑒/+ (digenic)
(36) Sfrp1, Sfrp2 (digenic)
(37) Shroom3
(38) Sp8
(39) Spint2 (HA12)
(40) T (Tc/tw5 mutant)
(41) Terc
(42) Traf4
(43) Trpm6
(44) Tulp3
(45) Tulp3 (hhkr mutant)
(46) vlmutant
(47)Wnt3a (vt mutant hypomorph)
(48) Zfhx1a
(49) Zic2 hypomorph
(50) Zic2Ku
(51) g2e
(52) 1B
(53) 97c2
Table 2: Continued.
Mouse models
Mouse strain (1 gene)
(54) NOD
PCP genes (4 genes)
(55) Lp, Crcmutants (digenic, heterozygous)
(56) Lp, Ptk7 (digenic, heterozygous)
(57) VanglLp/+, Sec24b+/− (digenic)
(58) VanglLp/+, Sfrp1−/−, Sfrp2+/−, Sfrp5−/− (4 genes)
Lethal before gestation day 12 (3 genes)
(59) Brca1
(60) Fgfr1 (alpha isoform)
(61) 22C
Spina bifida occulta (13 genes)
(62) Foxc1 (chmutant)
(63) Foxc2
(64) Lrp6
(65) Nog
(66) Pdgfra
(67) Pdfgc
(68) Pkd1
(69) Prrx1
(70) snomutant
(71) Tgfb2
(72) T (Tc/+ mutant)
(73) Traf4
(74) Zic1
Mouse models studied in nutrient supplement rescue (5 genes)
(1) Sp2Hmutant at Pax3 gene
(2) Spmutant at Pax3 gene
(3) Axdmutant
(4) ct mutant (hypomorph at Grhl3)
(5) Grhl3 null
Convergent extension leads to narrowing and lengthen-
ing of the neuroepithelium, a process that has been suggested
also to assist neural fold elevation via axial elongation [105,
226–228]. However, the lengthening of the body axis is
disrupted by manipulation of gene function required for
convergent extension; whilst the neural folds are still able
to elevate, convergent extension still fails [227, 229, 230].
Hence, convergent extension and neural fold elevation are
separable processes. Elevation of the neural folds at high
levels of the spinal neuraxis results from the formation of a
median hinge point (MHP) (Figure 3(b)) in a process termed
Mode 1 neurulation [215, 231, 232]. The neural folds remain
straight along both apical and basal surfaces, resulting in a
neural tube with a slit-shaped lumen. Mode 1 neurulation
occurs during formation of the spinal neural tube in 6–10-
somite stage embryos, as shown in Figures 4(a) and 4(b).
A second set of hinge points are formed dorsolaterally
at more caudal levels of the spinal neuraxis, the dorsolateral
hinge points (DLHPs), a process that appears to enhance the
ability of the apposing tips of the neural folds to come close to
each other (Figure 3(c)). Mode 2 occurs during formulation
of the spinal neural tube in 12–15-somite stage embryos and
generates a diamond-shaped lumen, as depicted in Figures
4(c) and 4(d). InMode 2, amedian hinge point is also present,
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Figure 2: Points of closure in the mouse embryo and phenotypes of failure of closure of the various points along the neuraxis. (a) Schematic
figure illustrating the multiple points of closure of the neural tube, directions of closure, and the different locations of neuropores in the
developing embryo. (1), site of closure (1) which occurs at the level of somite 3 in the 6-7-somite embryo. Closure (1) is the initiation event
of neurulation. Closure then progresses caudally and is completed by closure of the posterior neuropore (PNP) at the 29-30-somite stage of
development; (2), second closure site at around the 10-somite stage; (3), closure (3) site which begins soon after closure (2). Arrows depict
spreading of neural tube closure to neighbouring regions with completion of anterior neuropore closure soon after initiation of closure (3)
and closure of the hindbrain neuropore at the 18–20-somite stage. (b) Phenotype resulting from failure of closure (1): craniorachischisis;
(c) phenotype resulting from failure of closure (2): exencephaly; (d) phenotype of failure of the caudal wave of spinal closure, leading to an
enlarged PNP and later development of spina bifida. (A), posterior neuropore; (B), branchial arches; (C), developing heart; (D), hindbrain;
(E), midbrain; (F), forebrain; ANP: anterior neuropore; HNP: hindbrain neuropore.
whereas the remaining portions of the neuroepithelium do
not bend. At the 17–27-somite stage, the neural tube closes
without a median hinge point, whereas dorsolateral hinge
points are retained. This is known as Mode 3 neurulation
and generates an almost circular shaped lumen, as shown in
Figures 4(e) and 4(f).
Adhesion of the tips of the apposing neural folds is the
final step in primary neurulation, enabling the neural tube
to complete its closure [215]. The tips of the apposing neural
folds and the eventual point of adhesion are reported to
contain cell to cell recognition molecules (as demonstrated
in red in Figure 3(c)) which may be required for the specific
adhesion process to occur [233–243]. This is supported by
previous evidence that the cell surface of the neuroep-
ithelium is lined by carbohydrate-rich material that is not
observed in the rest of the neuroepithelium [238]. Removal of
GPI-anchored proteins from the cell surface during neuru-
lation results in delayed spinal neural tube closure [244].
Interestingly, work performed by Abdul-Aziz et al. and
Pyrgaki et al. demonstrated protrusions emanating from the
neural fold tips that interdigitate leading to eventual adhesion
[244, 245] (Figure 3(d)). Ultimately, the newly formed neural
tube undergoes remodelling via apoptosis to enable the
neural tube to separate from its surface ectoderm [228, 246]
(Figure 3(e)).
8.3. Primary Neurulation Versus Secondary Neurulation. Pri-
mary neurulation and secondary neurulation are important
developmental processes and have been described in many
models. In the chick, there does not exist a clear distinction
as to when primary neurulation ends and secondary neu-
rulation begins; the lower spinal cord has been described
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Figure 3: Schematic representation of the formation of the mouse spinal neural tube. Process of closure of the PNP of embryos undergoing
Mode 1 (a, b, d) or Mode 2 (a, c, d) neurulation. (a) Neuroepithelium thickens and converges; (b) formation of bilateral neural folds which
are elevated (Mode 1); (c) apposing tips of neural folds aided by bending at the dorsolateral hinge points (DLHP) of the bilateral neural folds
(Mode 2); (d) adhesion and fusion at the tips of the neural folds; (e) remodeling of the neural tube. Ne, neuroepithelium; Se, surface ectoderm;
Me, mesoderm; MHP, median hinge point; DLHP, dorsolateral hinge points; POAF, point of adhesion and fusion; Nt, notochord.
as junctional neurulation, whereby ingression and accretion
accompany the process of defining the area which straddles
primary and secondary neurulation and is therefore thought
to somehow represent human thoracolumbar spina bifida
[247].
In mouse and humans, spina bifida occulta has largely
been described as a result of failure of secondary neurulation
[3, 215]. However, much has been described of the severity of
lipomyelomeningocele [131, 248] in comparison to the some-
what neurologically unperturbed tethered cord phenomenon
which is brought on by trapped nerves due to missing
vertebral arches [133]. What is evident is that, irrespective of
whether or not there is skin covering the neural tube defect
lesion, the severity of the condition depends on the level
where the site of the lesion is located. Secondary neurulation
in the mouse is described as occurring at sacral level 2 [224].
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Figure 4: Schematic figure showing progressive developmental stages of the mouse embryo and sections through the PNP at these stages.
(a) Schematic of embryo at 6–10-somite stage, which has already undergone closure (1); (b) section through PNP of (a), depicting Mode 1
neurulation; (c) schematic of embryo at 12–15-somite stage; (d) section through PNP of (c) exhibiting Mode 2 neurulation; (e) schematic of
embryo which has undergone closures (1), (2), and (3) with PNP being the only remaining unfused section of the neural tube; (f) section
through PNP of (e) depicting Mode 3 neurulation.
Therefore, to describe lipomyelomeningocele as resulting
from failure of secondary neurulation would be artificial.
9. The Genetics behind the Structural
Changes in Spinal Neural Tube Closure
This section summarizes the various genes that are switched
on during neurulation and whose functions have been impli-
cated in the various structural changes that the spinal neural
tube undergoes in order for closure to be achieved.
9.1. PlanarCell Polarity andConvergent Extension. Planar cell
polarity (PCP) is a process in which cells develop with uni-
form orientation within the plane of an epithelium [249].The
PCP pathway is a noncanonicalWnt pathway [225, 250–252].
Various Wnt molecules are known to play roles in the PCP
pathway such as Wnt11 and Wnt5a [250, 253].
PCP signaling has been suggested to be primarily
required for cytoskeletal activity, for example, cellular pro-
trusion, cell-cell adhesion, and cell-matrix adhesion [254].
Skin development, body hair orientation, polarization of the
sensory epithelium in the inner ear, and the directed move-
ment of mesenchymal cell populations during gastrulation
are among the processes requiring proper PCP signaling in
vertebrates [227, 254–256]. In vertebrates, function of the
PCP pathway appears to be required for convergent extension
(CE). Lamellipodia have been the type of cell shown to drive
CE. These broad sheet-like protrusions exert traction on
adjacent mesodermal cells causing mediolateral intercalation
[257–259]. PCP signaling causes the regulation of cytoskeletal
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organization that redistributes subcellular PCP components
asymmetrically causing polarization of these cells [260].
Moreover, components of the signaling cascade converge or
are expressed asymmetrically in the lamellipodia [250, 253].
Among the genes implicated in this net movement of
cells, known as convergent extension, are 2 asymmetric
molecular systems that control PCP behaviour, the “core”
genes and the “Fat-Dachsous” PCP system [261, 262]. The
“core” genes give rise to multipass transmembrane proteins:
Frizzled (Fzd-3, -6, and -7), Van Gogh (Vangl-1 and -2),
Flamingo (Celsr-1, -2, and -3), and cytosolic components,
Dishevelled (Dvl-1, -2, and -3), Diego (Inversin), and Prickle
(Pk-1 and -2) [263]. The Fat-Dachsous (Ft-Ds) pathway
includes the large protocadherins Ft and Ds, acting as its
ligand, and Four-jointed (Fj) as a Golgi resident transmem-
brane kinase [264]. Downstream of the PCP system are PPE
(Planar Polarity Effector) genes: Inturned (In), Fritz (Frtz),
and Fuzzy (Fy) [265, 266].TheMultipleWing Hairs (mwh) act
downstream of both PCP and PPE [267] with Wnt4, Wnt5a,
Wnt7a, and Wnt11 as regulators [263].
Vangl-2 (formerly known as Ltap and Lpp1) has been
identified as the causative gene in the loop-tail mouse
[105, 268, 269]. Mutations in Celsr-1 cause craniorachis-
chisis in the Crash mouse [270]. The Dvl-1/Dvl-2, Dvl-
2/Dvl-3, Dvl-2/Vangl-2, and Fzd-3/Fzd-6 double knockout
mice also have severe NTD forms, mainly craniorachischisis
and exencephaly [269, 271–273]. The Vangl-1 and Vangl-
2 compound heterozygote exhibits craniorachischisis [274].
The noncore PCP genes also exhibit severe NTD in their
mouse mutants including Protein Tyrosine Kinase 7 (PTK7),
Scribbled PCP protein, the gene responsible for the circle tail
mouse phenotype, Scrib, andDishevelled BindingAntagonist
of Beta-Catenin 1 (Dact-1) [252, 270, 274–277]. All of these
genes have been implicated in the PCP pathway. Failure of
convergent extension results in an open neuraxis (the entire
neural tube from midbrain to low spine remains exposed)
and a shortened embryo, more commonly described as
craniorachischisis.
9.2. Neural Fold Elevation and Bending. Dorsoventral pat-
terning in the neural development of vertebrates is controlled
by the induction and polarizing properties of the floor plate
[278]. Expression of various genes such as sonic hedgehog
(Shh), bone morphogenetic protein (BMP) 7, HNF3𝛽, and
Vangl-1 emanating from the notochord and floor plate is
thought to cause cell specification which influences the
morphogenesis of the neural tube [106, 107, 112, 113, 252].
The floor plate and notochord appear to control the pattern
of cell types that appear along the dorsoventral axis of the
neural tube [226, 278]. Morphogenesis of the spinal neural
tube, in particular, the formation of the median hinge point
(MHP), is most likely a nonneuroepithelial cell autonomous
action as it is dependent on the differentiation of ventral cell
types by signals transmitted from axial mesodermal cells of
the notochord to overlying neuroepithelial cells [278–284].
Implantation and ablation experiments which manip-
ulated the notochord in both chick and mouse embryos
[221, 284–287] verified that the notochord is required for
formation of the MHP. It was proposed that the notochord
releases a morphogen that may regulate MHP formation.
Shh protein is expressed in the notochord at this stage
[113, 288] and application of either Shh-expressing cells or
purified protein to intermediate neural plate explants leads
to induction of the floor plate [113], suggesting that Shh is
the MHP-inducing morphogen. However, MHP formation is
not totally abolished in Shh-null mouse embryos, suggesting
that other factors from the notochord may also have MHP-
inducing properties [287].
The second site of neural fold bending as described in
Section 8.2 and Figure 3(c) is the dorsolateral hinge point
(DLHP). Bending of the neuroepithelium at the DLHP is
regulated by mutually antagonistic signals external to the
neural fold, as reviewed by Greene and Copp [224, 289]. In
contrast to midline bending, Shh has been shown to inhibit
dorsolateral bending in the mouse [287] consistent with an
absence of NTDs in Shh-null embryos. Signal(s) arising from
the surface ectoderm (SE) comprise(s) a second antagonistic
signal involved in the regulation and formation of the DLHPs
[290].This has been suggested as further evidence that bend-
ing of the neural folds involves signaling from the SE. Bone
morphogenetic proteins (BMPs) are candidates to mediate
this signaling. Three BMPs (BMP2, BMP4, and BMP7) are
expressed in the spinal neural tube. BMP2 and BMP7 are
expressed in the surface ectoderm adjacent to the open spinal
neural tube, while BMP4 is expressed in the surface ectoderm
overlying the closed spinal neural tube [291].
Recent studies suggest that Noggin may also play a role
in regulating DLHP formation [292, 293]. Noggin is an
inhibitor of BMP signaling and is expressed at the tips of
the apposing neural folds [293, 294]. Homozygous mouse
embryos null for Noggin exhibit both exencephaly and spina
bifida (100%) [292, 295]. However, spina bifida does not arise
in homozygous Noggin mutants until embryonic day 11-12
when the neural tube ruptures. The spinal neural tube of
homozygous null Noggin embryos during neurulation takes
on the appearance of a wavy neural tube before the neural
tube reopens [293], possibly suggesting an unstable initial
closure mechanism. Shh works in an antagonistic manner
towardsNoggin, as doesNoggin towardsBMP signaling [296].
This suggests that Nogginmay facilitate bending of the spinal
neural tube [293] by overcoming the inhibitory influence of
BMPs.
Stottmann et al. [293] suggest that the spinal defect in
Noggin null embryos results from a failure to maintain a
closed neural tube due to a defective paraxial mesoderm
[293]. Yip et al. [297] also had shown that the mesodermal
extracellular matrix plays an important role in maintaining
neuroepithelial rigidity of the spinal neural tube during
neurulation [297]. Embryos were cultured in the presence
of chlorate, which functions to inhibit sulfation of heparan
sulphate proteoglycans (HSPGs) in the extracellular matrix
of the mesoderm. This treatment not only resulted in an
expedited bending of the DLHPs but also elicited an unnat-
ural shape of neural tube due to a convex shaped mesoderm.
However, removal of the paraxialmesodermdoes not prevent
closure of the spinal neural tube [287].
Interestingly, there are 3 genes which, when mutated, not
only affect paraxial mesoderm production in the mouse [109,
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292, 298] but also result in an NTD phenotype in the mouse.
These are Cyp26, Noggin, and Fgfr1 [94, 109, 293]. TheWnt3a
[299], Lef1/Tcf1 double null [108] and Raldh2 [300] mutants
also have defective paraxial mesoderm production, with an
abnormal neural tube during neurulation. Whether or not
the paraxial mesoderm plays a primary role in successful
neurulation in these mutants remains unknown.
Neural tube closure does not depend exclusively on the
MHP or DLHPs, since closure can occur in the absence
of either, as in Mode 3 and Mode 1 spinal neurulation,
respectively. However, cell shape changes of some type,
affecting morphogenesis of the spinal neural tube, are clearly
required for closure to occur in all species studied, including
the mouse [254]. Table 5 demonstrates the lack of specific
expression of genes at the DLHPs. However, overlapping
gene expression throughout the neuroepithelium and tips of
neural foldsmay facilitate the bendingmechanism seen in the
DLHPs.
9.3. Adhesion of the Neural Folds. In all animal species
studied, a zone of altered cell morphology with numerous
rounded cell blebs has been observed along the tips of
the spinal neural folds, immediately prior to adhesion. The
observed surface alterations may reflect a change in the
properties of the cells at the adhesion site which correlate
with initial adhesion between the folds [234, 236, 301, 302].
Structural observations of the point of adhesion in human
embryos have yet to be reported, possibly due to insufficient
or poor preservation of material so that surface structures
cannot be observed.
Adhesion is the final process in the sequence of primary
neurulation events. Suchphysical zippering state of the neural
tube has been suggested, in previous studies, as evidence that
neural tube closure is a continuous process [303]. However, a
debate exists as towhether the physical process of neurulation
actually equates to continuous zippering or, more accurately,
to a button-like process in which neural tube adhesion
initially occurs at various slightly separated points along the
axis. According to the latter idea, neural tube adhesion is
actually a discontinuous process of closure [222].
PCP regulation may play a role in adhesion and fusion
as suggested in both zebrafish and Xenopus studies. Firstly,
cell division regulated by PCP signaling leads to rescue
of neural tube morphogenesis in the trilobite zebrafish
mutant [304]. Secondly, the Xenopus adhesion molecules,
NF-protocadherin, and its cytosolic partner TAF1/Set have
been suggested to participate in CE after the neural folds are
formed. Disruptions in NF-protocadherin and TAF1 can lead
to a shortenedAP axis that was not evident until stages 22–25,
some time after neural tube closure [305].
Ultrastructures that emanate from the neural folds at the
site of closure have been regarded as a secondary process in
the frog. This is because wound healing which acts via actin
purse-string contraction is thought to be the primary cause of
closure in the frog neural tube [306]. Adhesion of the neural
tube and epidermis have been suggested to be separate events
based upon the observation that the epidermal ectoderm is
still able tomigrate and cover the open neural tube in both the
chick and the frog [302, 305]. However, the issue of whether
or not the neural folds could adhere even in the absence of
epidermal fusion in both the chick and the frog has yet to be
answered.
Adhesion in the neural tube of rodents has been described
previously but the mechanism of this highly specialized
process is poorly understood [103, 240, 243, 301, 307, 308]. In
a recent study, a direct requirementwas shown for the binding
of a specific ligand (ephrinA5) to a specific type of receptor
(EphA7) in order to enable adhesion to occur in the neural
tube [243].
Cell to cell adhesion provides impetus for positional cell
migration [309]. This may suggest that PCP driven events in
the surface ectodermmay play a role in neural tube closure, as
suggested in the chick embryo [310]. Epidermal constriction
has also been shown to be crucial for spinal neural tube
closure in the frog, while the surface ectoderm was shown
to be necessary for spinal neural tube closure in the mouse
[287, 311].
10. Mouse Mutant Models with a Spinal
Defect, Not a Neural Tube Defect
Table 4 summarizes the ten mouse mutant models that
exhibit a spinal defect alone. Spinal defects encompass
mouse mutants with spina bifida (without any other NTD
phenotype, e.g., exencephaly and/or craniorachischisis) and
abnormal spinal neural tubes with no spina bifida.
The mutants which display only spina bifida are the
FGFR1𝛼 chimeric mutant [94], Traf4 mutant [95], the Shp2
chimeric mutant [96], the axial defects mutant [97], glial cell
missing-1 [98], and vacuolated lens [99].
All of these mutants have spina bifida, which denotes
incomplete closure of the spinal neural tube. A large majority
(4 out 6 of these mutants which have only spina bifida) have
a second phenotype that is a second neural tube. Vacuolated
lens mutant embryos develop spina bifida and, in addition,
an ectopic neural tube is observed, ventral to the open neural
tube [99]. In Shp2, FGFR1𝛼, and vacuolated lens mutants,
an ectopic neural tube is observed during the period of
neurulation between E8.5 and E9.5 [94, 96]. In contrast, an
ectopic neural tube has only been observed at E12.5 and later
stages in Gcm1 mutant embryos [98].
The prevalence of an ectopic neural tube in 2 out of 6
mutants at E9.5–E10.5 seems to suggest that a second neural
tube may be a common occurrence and that this predispo-
sition may be the result of an underlying fault in primary
neurulation instead of failure of secondary neurulation.
There are many different examples of mouse mutants in
which the caudal neural tube is abnormal but the phenotype
differs from spina bifida. In many cases, these are described
as spinal neural tube defects [100–103]. Apart from the 3
mutants with only spina bifida (Fgfr1, Shp2, andGcm1) which
have 2 neural tubes with one notochord, 2 othermutants with
spinal defect but no spina bifida share the same predicament.
These are the EphA2 null mouse [101] and PAK4 null mouse
[100]. Another abnormal spinal neural tube phenotype is a
wavy spinal neural tube that occurs in the WASP null mouse
and the Vinculin null mouse [102, 103]. Vinculin is a large
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Table 4
Mutant name Genemutated
Function of
protein
Possible
mechanism
of NTD
Schematic representations of
ectopic spinal neural tube
Rate of
occurrence of
spina bifida
Phenotype
and reference
Fibroblast
growth factor
receptor 1
(knockout
producing
chimeras)
Fgfr1 Growth factorreceptor
Unknown
(NTDs occur
only in
chimaeras)
or
E10.5, 29.5%
have spina
bifida and
15% have
ectopic
neural tube
Spina bifida,
second NT;
NT in NT &
kinky tail
[94]
Tumour
necrosis factor
receptor
associated factor
4
(knockout)
Traf4 Intracellularsignaling adaptor Unknown No ectopic neural tube
40%
homozygous
nulls have
spina bifida
Spina bifida
[95]
Shp2
(knockout
producing
chimeras)
Shp2
Tyrosine
phosphatase
(dephosphorylates
proteins)
Unknown
(NTDs occur
only in
chimaeras)
E10.5, 36% of
high content
chimeras
have second
neural tube
and 59% have
spina bifida
Spina bifida,
second NT
[96]
Axial defects
(spontaneous
mutant; gene
not identified)
ND ND ND No ectopic neural tube
10%
penetrance in
CD1
Spina bifida
[97]
Glial cells
missing-1
(knockout)
Gcm1
Transcription
factor
Ectopic
expression
causes NTDs
by unknown
mechanism
and
25.8%
transgenics
have spina
bifida; 100%
transgenics
have ectopic
neural tube
Spina bifida;
multiple NT
[98]
Vacuolated lens
(spontaneous
mutant)
ND ND
Suggested
failure in
apposition
and fusion?
50% of
homozygous
nulls show
spina bifida at
12 dpc
Spina bifida
[99]
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Table 4: Continued.
Mutant name Genemutated
Function of
protein
Possible
mechanism
of NTD
Schematic representations of
ectopic spinal neural tube
Rate of
occurrence of
spina bifida
Phenotype
and reference
PAK4
(knockout) PAK4
Cytoskeletal
organization
Target for
Rho GTPase
Cdc42 None
Double
neural tube
with one
notochord
No spina
bifida
[100]
EphA2
(knockout) EphA2
Adhesion and
fusion?
Receptor
tyrosine
kinase None
Kinky tail
with double
neural tube
No spina
bifida
[101]
WASP
(knockout) WASP
Cytoskeletal
organization
Formation of
cell-surface
projections
(filopodia)
required for
cell
movement
and
actin-based
motility
None
Wavy neural
tube
No spina
bifida
[102]
Vinculin
(knockout)
(E10 Lethal)
Vinculin Cytoskeletalorganization
Major
constituent of
cell junctions
(cell matrix &
cell-cell)
None
Wavy neural
tube
No spina
bifida
[103]
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Table 5
Neural tube structure Genes expressed at
Neuroepithelium
Zic2 [104]
Vangl2 [105]
Floor plate and notochord
HNF3 [106]
Vangl1 [107]
Wnt3a [108]
Cyp26a1 [8, 109]
Shh [11]
Map3k4 [110]
Marcksl1 (Mlp) [18, 111]
Traf4 [21, 95]
Notochord
BMP7 [112]
Brachyury [6]
Shh [10, 11, 113, 114]
Surface ectoderm
Fgf8 [115]
Grainyhead-like 2 [116]
BMP7 [104]
Wnt6 [104]
Notch1 [108]
Dorsolateral hinge points
None
Tips of neural folds at E9.5
Axin2 [117]
Pax3 [118]
Dorsal roof of closed neural tube bridge
Zic2 [104]
Msx1 [104]
Wnt1 [9, 119]
BMP6 [119]
Tips of neural folds (surface ectoderm)
Grainyhead-like 3 (in neural ectoderm at E8.5) [116]
Par1 and Par2 [120]
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protein that binds multiple cytoskeletal proteins, actin, 𝛼-
actinin, talin, paxillin, VASP, ponsin, vinexin, and protein
kinase C (PKC)which have been suggested to be the adhesion
scaffold that connects early adhesion sites to actin-driven
protrusive machinery in enabling motility [312].
Abnormal and ectopic spinal neural tubes may be
regarded as variant forms of NTDs as it may be possible that
the neural tube reopens after closure due to various reasons.
Ectopic neural tube may take on many different variations
apart from the expected second or multiple neural tubes.
Among them are a neural tube positioned above another
neural tube as well as a wavy neural tube phenotype that
is observed in many knockout mice with NTDs. The wavy
region in these knockout mice has not had its spinal neural
tube sectioned; thus it remains unknown whether the neural
tube remains adhered. Spina bifida occulta in humans is
usually accompanied by various physical abnormalities such
as lipoma, rachischisis, hair tufts, ectodermal sinuses, skin
pigmentation, or diastematomyelia. These associated defects
occur in either syndromic or nonsyndromic NTDs. However,
they may be missed and not categorized properly in cases
of transgenic mice with possible NTDs. There is only one
example of a null mouse in which these abnormalities have
been well described which is the Gcm1 mouse mutant that
exhibits both open (meningomyelocele) and close (lipoma
and diastematomyelia) spina bifida in its litters [98].
11. Haploinsufficiency in Mouse and Man
Haploinsufficiency is poorly studied in both man andmouse.
Furthermore, the study of the occurrence of spina bifida
in genes acting in an additive or subtractive manner is
almost unknown. Currently, there are 5 studies in the mouse,
which have demonstrated spina bifida and the interaction of
the involved genes mechanistically. These include Lrp6 and
Wnt5a [313], Zac1 and Suz12 [314], Hira and Pax3 [315], Rybp
encompassing Ring1 and YYP1 [316], and haploinsufficiency
of the components in the primary cilium of the hedgehog
pathway [317].
The scenario in humans is somewhat similar in that
there are 4 studies to date demonstrating the involvement of
haploinsufficiency in the causation of spina bifida. The Pax3
gene and the EphA4 gene act in concert with each other in
causing spina bifida due to interstitial deletion at position
2q36 [318]. Furthermore, in the same paper, Goumy et al.
[318] suggested that a similar phenomenon occurs in the
mouse when taking into account the spina bifida phenotype
seen on the Splotch mouse that is affected by both Pax3 [93]
and EphA4 [319], albeit the link between the two in themouse
has yet to be ascertained. The hedgehog pathway has also
been implicated in humans, where spina bifida occurs when
Patched is perturbed when implicated with Gorlin syndrome
[320]. The third and fourth studies implicating human spina
bifida involve haploinsufficiency in the region of 13q [321] and
7q [322].
12. Conclusion
This review paper aims to probe spina bifida, the surviving
form of neural tube defects, closely and to analyze the
relationship of what can be learnt from the mouse model of
spina bifida and to use that knowledge in order to shine a
brighter understanding with regard to the human form.
What is very obvious is that there have been amultitude of
genes (74 according to this review) which regulate specifically
spina bifida in themouse.This is a very high number of genes;
therefore the take homemessagewould be in our opinion that
there are a multitude of genes that can, if perturbed, cause
spina bifida. Whether or not these genes cause the condition
or are in fact a player in a pool of numerous genes, which can
do the job of closing the spinal neural tube, is a tantalising
idea. Therefore, we put forth the idea that perhaps these 74
may be working with other genes in their family or other
genes which share a common pathway in order to close the
neural tube. Furthermore, the idea of gene-gene interaction
which promotes heterogeneity among genes is incomplete
without also considering the idea of haploinsufficiency of
genes, where many mutations in mankind are somehow
protected from having a deleterious phenotype by having
other genes compensate the job of the gene or genes being
perturbed. A very good example of this would be the Vangl-
1 and Vangl-2 compound heterozygote mouse mutant which
lacks a single allele of both Vangl-1 and Vangl-2; therefore the
probability that the 2 genes compensate each other is high
and both genes are required in a certain amount of dose,
lack of which translates into a neural tube defect phenotype.
Therefore, the mouse model which examines the delineation
of genes has not completed its true worth until scientists
understand the biology of the disease or condition better
by also taking into account (i) the amount (the functioning
allele) of the said gene and (ii) the interactionwith other genes
in its family which may be able to compensate its function
as well as (iii) the interaction with other genes which share a
commonpathway.Themouse is a powerful tool to study spina
bifida because it is amammal like humans and its embryology
is similar to humans and therefore it is an indispensable
tool to mechanistically study the structural changes involved
in spinal neural tube closure. The genes involved in spinal
neural tube defects may differ in man and mouse; however,
parallels may be drawn between the principles of how the
genes interact in influencing spinal neural tube closure in
both man and mouse.
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